Inventiva (NASDAQ:IVA) Shares Gap Down – Time to Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $6.83, but opened at $6.38. Inventiva shares last traded at $6.29, with a volume of 217,467 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Wolfe Research upgraded Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Guggenheim cut their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Barclays initiated coverage on shares of Inventiva in a research note on Tuesday. They set an “overweight” rating and a $18.00 price objective for the company. UBS Group started coverage on Inventiva in a research note on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright set a $24.00 price target on Inventiva and gave the company a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $16.22.

Inventiva Trading Down 5.7%

The stock’s 50 day simple moving average is $4.96 and its two-hundred day simple moving average is $4.77.

Hedge Funds Weigh In On Inventiva

Hedge funds have recently modified their holdings of the stock. UBS Group AG grew its stake in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after acquiring an additional 2,634,580 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Inventiva during the 3rd quarter valued at about $116,000. Millennium Management LLC purchased a new position in shares of Inventiva during the third quarter valued at about $649,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Inventiva by 55.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Inventiva in the second quarter worth about $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.